Corporate ActionJun 2, 2026, 12:20 PM
Bluejay Diagnostics Raises $8.5M in Private Placement
AI Summary
Bluejay Diagnostics, Inc. announced it has entered into definitive agreements for a private placement, expecting to raise $8.5 million in gross proceeds upfront. The offering includes 3,655,917 shares of common stock (or pre-funded warrants) and accompanying Series G and H warrants, with a purchase price of $2.325 per share. The company could receive an additional $15.1 million if the warrants are fully exercised. These funds are projected to extend Bluejay's cash runway into the first quarter of 2027, beyond its expected FDA submission, and will be used for FDA approval processes, research and development, and general working capital.
Key Highlights
- Bluejay Diagnostics secured $8.5 million in gross proceeds from a private placement.
- Potential additional gross proceeds of approximately $15.1 million upon full exercise of warrants.
- The offering includes 3,655,917 shares (or pre-funded warrants) and Series G and H warrants.
- Purchase price for shares/pre-funded warrants is $2.325; warrant exercise price is $2.075.
- Net proceeds are expected to extend the cash runway into Q1 2027, beyond expected FDA submission.
- Funds will support FDA approval activities, R&D, and general working capital.
- The private placement is anticipated to close on or about June 3, 2026.
Price Impact
More from BJDX